Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RPID 
Rapid Micro Biosystems Inc (RPID)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: RPID (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8
1 Year Target Price $8
| 3 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 113.2% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 133.74M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 3 | Beta 1.3 | 52 Weeks Range 0.83 - 4.50 | Updated Date 09/14/2025 |
52 Weeks Range 0.83 - 4.50 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -145.63% | Operating Margin (TTM) -167.28% |
Management Effectiveness
Return on Assets (TTM) -29.89% | Return on Equity (TTM) -59.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 108060241 | Price to Sales(TTM) 4.42 |
Enterprise Value 108060241 | Price to Sales(TTM) 4.42 | ||
Enterprise Value to Revenue 3.57 | Enterprise Value to EBITDA 0.82 | Shares Outstanding 39710800 | Shares Floating 19338040 |
Shares Outstanding 39710800 | Shares Floating 19338040 | ||
Percent Insiders 9.6 | Percent Institutions 59.55 |
Upturn AI SWOT
Rapid Micro Biosystems Inc
Company Overview
History and Background
Rapid Micro Biosystems, Inc. was founded in 2006. It focuses on developing and providing automated microbial detection and enumeration technologies for biopharmaceutical manufacturing.
Core Business Areas
- Growth Direct Platform: An automated system for rapid microbial detection and enumeration used in quality control labs for biopharmaceutical manufacturing.
Leadership and Structure
The company has a board of directors and an executive management team responsible for overseeing operations and strategy. Sean Witek is the CEO. The structure is typical of a publicly traded company with functional departments like R&D, sales, and marketing.
Top Products and Market Share
Key Offerings
- Growth Direct System: The Growth Direct system automates and accelerates microbial detection and enumeration, eliminating manual steps. Market share data is not publicly available. Key competitors include bioMu00e9rieux, Charles River Laboratories, and Sartorius. Revenue data is proprietary but constitutes the majority of the company's revenue.
Market Dynamics
Industry Overview
The biopharmaceutical manufacturing industry is heavily regulated, requiring stringent quality control measures. Microbial contamination testing is critical. There's a growing trend towards automation and rapid testing methods.
Positioning
Rapid Micro Biosystems is positioned as an innovator in rapid microbial detection, offering a solution to improve efficiency and reduce time-to-results. Its competitive advantage lies in its automated technology compared to traditional manual methods.
Total Addressable Market (TAM)
The TAM for microbial detection in biopharmaceutical manufacturing is estimated to be in the billions of dollars. Rapid Micro Biosystems is positioned to capture a portion of this TAM through its automated technology.
Upturn SWOT Analysis
Strengths
- Automated technology
- Rapid results
- Reduced manual labor
- Improved accuracy
- Strong focus on biopharmaceutical manufacturing
Weaknesses
- Limited product portfolio
- High price point potentially limiting adoption
- Dependence on the biopharmaceutical industry
- Relatively small company size
Opportunities
- Expanding product applications
- Geographic expansion
- Partnerships with other companies
- Increasing demand for automation in biopharmaceutical manufacturing
- Penetration of the Cell & Gene Therapy testing market.
Threats
- Competition from larger companies
- Technological advancements from competitors
- Economic downturn impacting biopharmaceutical investment
- Changes in regulatory requirements
Competitors and Market Share
Key Competitors
- BIO
- CRVS
- Sartorius
Competitive Landscape
Rapid Micro Biosystems faces competition from larger, more established companies with broader product portfolios. However, its automated technology offers a competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends require specific financial data unavailable currently.
Future Projections: Future growth projections require analyst estimates unavailable currently.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts, product development, and strategic partnerships.
Summary
Rapid Micro Biosystems is a niche player in the microbial detection market, focusing on automation for the biopharmaceutical industry. Its strength lies in its innovative technology, but its small size and limited product portfolio pose challenges. To succeed, the company needs to expand its applications, geographic reach, and partnerships while navigating competition from larger players. Future growth will depend on continued adoption of automated testing methods in biopharmaceutical manufacturing.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Financial News Sources
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise. Financial data may be delayed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rapid Micro Biosystems Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2021-07-15 | CEO, President & Director Mr. Robert G. Spignesi Jr. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 163 | Website https://www.rapidmicrobio.com |
Full time employees 163 | Website https://www.rapidmicrobio.com | ||
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.